Evidence map›Paper›PMID 34884728›Full record

ArticleInternational journal of molecular sciences2021

Targeting S100A9 Reduces Neutrophil Recruitment, Inflammation and Lung Damage in Abdominal Sepsis.

Zhiyi Ding, Feifei Du, Richard Garland Averitt V, Gabriel Jakobsson, Carl-Fredrik Rönnow, Milladur Rahman, Alexandru Schiopu, Henrik Thorlacius

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zhiyi DingDepartment of Clinical Sciences, Malmö, Section for Surgery, Lund University, 21428 Malmö, Sweden.
Feifei DuDepartment of Clinical Sciences, Malmö, Section for Surgery, Lund University, 21428 Malmö, Sweden.
Richard Garland Averitt VDepartment of Clinical Sciences, Malmö, Section for Surgery, Lund University, 21428 Malmö, Sweden.
Gabriel JakobssonDepartment of Clinical Sciences, Malmö, Lund University, 21428 Malmö, Sweden.ORCID 0000-0001-5071-9505
Carl-Fredrik RönnowDepartment of Clinical Sciences, Malmö, Section for Surgery, Lund University, 21428 Malmö, Sweden.
Milladur RahmanDepartment of Clinical Sciences, Malmö, Section for Surgery, Lund University, 21428 Malmö, Sweden.ORCID 0000-0002-8883-4848
Alexandru SchiopuDepartment of Clinical Sciences, Malmö, Lund University, 21428 Malmö, Sweden.ORCID 0000-0002-7587-5050
Henrik ThorlaciusDepartment of Clinical Sciences, Malmö, Section for Surgery, Lund University, 21428 Malmö, Sweden.
Malmö University · SE

Funding

Cancerfonden 190428 PjEinar and Inga Nilsson foundation N/AMaggie Stephens foundation N/AMAS Cancer Research Foundation N/ASwedish Research Council 2017-01621
6 · The paper itself

Abstract

S100A9, a pro-inflammatory alarmin, is up-regulated in inflamed tissues. However, the role of S100A9 in regulating neutrophil activation, inflammation and lung damage in sepsis is not known. Herein, we hypothesized that blocking S100A9 function may attenuate neutrophil recruitment in septic lung injury. Male C57BL/6 mice were pretreated with the S100A9 inhibitor ABR-238901 (10 mg/kg), prior to cercal ligation and puncture (CLP). Bronchoalveolar lavage fluid (BALF) and lung tissue were harvested for analysis of neutrophil infiltration as well as edema and CXC chemokine production. Blood was collected for analysis of membrane-activated complex-1 (Mac-1) expression on neutrophils as well as CXC chemokines and IL-6 in plasma. Induction of CLP markedly increased plasma levels of S100A9. ABR-238901 decreased CLP-induced neutrophil infiltration and edema formation in the lung. In addition, inhibition of S100A9 decreased the CLP-induced up-regulation of Mac-1 on neutrophils. Administration of ABR-238901 also inhibited the CLP-induced increase of CXCL-1, CXCL-2 and IL-6 in plasma and lungs. Our results suggest that S100A9 promotes neutrophil activation and pulmonary accumulation in sepsis. Targeting S100A9 function decreased formation of CXC chemokines in circulation and lungs and attenuated sepsis-induced lung damage. These novel findings suggest that S100A9 plays an important pro-inflammatory role in sepsis and could be a useful target to protect against the excessive inflammation and lung damage associated with the disease.

Indexed as

Acute Lung InjuryAnimalsCalgranulin BChemokines, CXCDrug Evaluation, PreclinicalInterleukin-6LungMaleMiceMice, Inbred C57BLNeutrophil InfiltrationSepsisSulfonamidesABR-238901Calgranulin BChemokines, CXCInterleukin-6interleukin-6, mouseS100A9 protein, mouseSulfonamidesinfectioninflammationleukocytelungsepsis

Identifiers

PMID34884728
PMCPMC8658007
OpenAlexW3215369806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.